Neuronetics, Inc. (STIM): Results of Operations and Financial Condition
Neuronetics, Inc. (STIM) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d78613dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Neuronetics Reports Second Quarter 2026 Financial and Operating Results MALVERN, PA., August 11, 2026 – Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”), a leader in interventional mental health that combine
How this was made
The 30-second read
Why it matters
The filing updates investors on profitability trajectory (adjusted EBITDA and operating loss improvement), cash position deterioration, and full-year guidance changes, which can drive re-rating of near-term execution risk.
Market read
Traders can reassess STIM’s execution against guidance using the disclosed Q2 metrics (revenue, gross margin, adjusted EBITDA, net loss) and the updated FY 2026 ranges, including cash flow expectations.
What to watch
Operating expense guidance excludes stock-based compensation, so investors should focus on GAAP operating loss trajectory and the pace of cash burn versus the stated cash flow range.
Background
Neuronetics operates NeuroStar TMS technology and the Greenbrook interventional psychiatry clinic network, and this 8-K reports Q2 2026 results plus FY 2026 outlook.
Ticker impact
Neuronetics reported Q2 2026 results and updated FY 2026 guidance, including revenue $160M-$164M and cash flow from operations and investing of negative $10.5M to negative $14.5M.
Likely positive near-term bias if investors view the EBITDA improvement and guidance tightening as credible progress toward profitability, but cash balance decline may cap upside.
The filing provides multiple decision-relevant datapoints: Q2 revenue growth (+9.1%), adjusted EBITDA improvement to $0.3M, net loss narrowing, and explicit FY 2026 guidance ranges plus a cash flow outlook.
Market effects
Signals improving unit economics and go-to-market execution for interventional mental health providers combining device sales with care-delivery networks.
No specific regional spillover beyond US small-cap healthcare sentiment.
Limited, as the disclosure is company-specific and not tied to global regulatory or supply-chain events.
Counterpoint
Despite improved adjusted EBITDA, the company still reported a net loss and reduced cash from $34.1M to $25.0M, so the market may discount the sustainability of progress.
Key entities
- issuerNeuronetics, Inc.
Reported Q2 2026 financial and operating results and provided updated FY 2026 guidance in an SEC 8-K.
- business_segmentGreenbrook
Clinic network segment; revenue grew to $26.9M in Q2 2026 and drove overall revenue growth.
- executiveNir Naor
Appointed Executive Vice President, Chief Financial Officer, Corporate Secretary, and Treasurer.
- executiveCory Anderson
Promoted to Executive Vice President and General Manager of Greenbrook clinics.
- executiveRob Greene
Appointed Senior Vice President, Sales.
